These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28278507)

  • 1. Improved Visual Outcome and Low Recurrence with Early Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor in Myopic Choroidal Neovascularization.
    Moon BG; Cho AR; Lee J; Kim YJ; Lee JY; Kim JG; Yoon YH
    Ophthalmologica; 2017; 237(3):128-138. PubMed ID: 28278507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
    Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FACTORS INFLUENCING NEED FOR RETREATMENT AND LONG-TERM VISUAL OUTCOME AFTER INTRAVITREAL BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Ng DS; Kwok AK; Tong JM; Chan CW; Li WW
    Retina; 2015 Dec; 35(12):2457-68. PubMed ID: 26035400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
    Yang HS; Kim JG; Kim JT; Joe SG
    Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS
    Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
    Ahn SJ; Park KH; Woo SJ
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
    Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.
    Cohen SY; Nghiem-Buffet S; Grenet T; Dubois L; Ayrault S; Fajnkuchen F; Delahaye-Mazza C; Quentel G; Tadayoni R
    Jpn J Ophthalmol; 2015 Jan; 59(1):36-42. PubMed ID: 25416566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FIVE-YEAR OUTCOMES OF INTRAVITREAL INJECTION OF RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION.
    Wu TT; Kung YH
    Retina; 2017 Nov; 37(11):2056-2061. PubMed ID: 28590318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
    Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
    Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization.
    Yoon JU; Byun YJ; Koh HJ
    Retina; 2010 Mar; 30(3):418-24. PubMed ID: 20094012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome.
    Ruiz-Moreno JM; Arias L; Montero JA; Carneiro A; Silva R
    Br J Ophthalmol; 2013 Nov; 97(11):1447-50. PubMed ID: 24026146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization.
    Kung YH; Wu TT; Huang YH
    Acta Ophthalmol; 2014 Dec; 92(8):e615-20. PubMed ID: 24924911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
    Lai TY; Chan WM; Liu DT; Lam DS
    Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre.
    Rishi P; Rishi E; Bhende M; Agarwal V; Vyas CH; Valiveti M; Bhende P; Rao C; Susvar P; Sen P; Raman R; Khetan V; Murali V; Ratra D; Sharma T
    Br J Ophthalmol; 2016 Oct; 100(10):1337-40. PubMed ID: 26792945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of the intravitreal injection of ranibizumab for the treatment of choroidal neovascularization secondary to pathologic myopia.
    Wasiluk E; Wojnar M; Obuchowska I; Mariak Z
    Int Ophthalmol; 2020 Apr; 40(4):833-839. PubMed ID: 31788714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
    Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
    Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Follow-Up of Choroidal Neovascularization due to Angioid Streaks with pro re nata Intravitreal Anti-VEGF Treatment.
    Giacomelli G; Finocchio L; Biagini I; Sodi A; Murro V; Introini U; Varano M; Bandello F; Menchini U
    Ophthalmologica; 2017; 238(1-2):44-51. PubMed ID: 28641290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA: SIX YEARS OUTCOME.
    Ruiz-Moreno JM; Montero JA; Araiz J; Arias L; García-Layana A; Carneiro A; Figueroa MS; Silva R
    Retina; 2015 Dec; 35(12):2450-6. PubMed ID: 26049616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.
    Lai TY; Luk FO; Lee GK; Lam DS
    Eye (Lond); 2012 Jul; 26(7):1004-11. PubMed ID: 22595908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.